메뉴보기
    HOME

    SEARCH

    • up
    • down
    [PUBLICATIONS]

    Lee H. Chapter 1. Disappearance of Biomedical Science, Destruction of Research Ethics. In: Hwang Woo Suk’s Scandal. Hannarae Publishing Co., Seoul, Korea (ISBN : 9788955660487)

    [PUBLICATIONS]

    Knollmann BC, Smyth B, Garnett C, Salessiotis A, Gvodjan D, Berry NS, Lee H, Min FD. Personal Digital Assistant-Based Drug Reference Software as Tools to Improve Rational Prescribing: Benchmark Criteria and Performance.Clin Pharmacol Ther 2005 Jul;78(1):7-18.

    [PUBLICATIONS]

    Lee H, Yim D-S, Zhou H, Peck CC. Evidence of Effectiveness: How Much Can We Extrapolate From Existing Studies? AAPS Journal.  2005 Oct 5;7(2):E467-74.

    [PUBLICATIONS]

    Lack NA, Green B, Dale DC, Calandra GB, Lee H, MacFarland RT, Badel K, Liles WC, Bridger G, A Pharmacokinetic/Pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, Clin Pharmacol Ther 2005;77(5): 427-36.

    [PUBLICATIONS]

    Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population Pharmacokinetic Analysis and Simulation of the Time Concentration Profile of Etanercept in Pediatric Patients with Juvenile Rheumatoid Arthritis, Journal of Clinical Pharmacology, 2005;45(3):246-256.

    [PUBLICATIONS]

    Lee H. Good Review Practices are the first step forward for the Korea Food and Drug Administration, Drug Information Journal 2005;39: 185-192.

    [PUBLICATIONS]

    Lee H. FDA vs. KFDA. The Young Physicians Press. Seoul, Korea, 2005 (ISBN : 8991232043)

    [PUBLICATIONS]

    Lee H, Kimko H, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003;73(4): 348-365.

    [PUBLICATIONS]

    Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Postmarketing Drug Dosage Changes of 499 FDA-Approved New Molecular Entities, 1980-1999, Pharmacoepidemiology and Drug Safety, 2002;11:439-446.

    [PUBLICATIONS]

    Lee H, Application of foreign clinical trial data by using pharmacokinetic-pharmacodynamic modeling and simulation technique in Korea: a regulatory point of view. Kor J Clin Pharmacol Ther, 2002; 10(2): 193-9.

    [PUBLICATIONS]

    Lee H, C Kim, S Shin. Changes in Clinical Trial Practice and the Working Environment in the Korean Pharmaceutical Industry Since the Implementation of Good Clinical Practice, Drug Info J, 2001;35:203-210.

    [PUBLICATIONS]

    Yoon YR, Cha IJ, Shon JH, Kim KA, Kim MJ, Shin JG, Park SW, Seo SS, Choi JS, Lee H. Clinical Pharmacokinetics of Transdermal Absorption of Diclofenac Diethylammonium Plaster in Healthy Volunteers, Kor J Clin Pharmacol Ther, 2000;8(1): 101-112.

    CCADD

    Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University

    Room C-208, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229, SOUTH KOREA (Gwanggyo)

    Room 406, Building 17, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, SOUTH KOREA (Yeon-gun)

    Tel: +82-31-888-9189 (Gwanggyo); +82-2-3668-7381 (Yeon-gun)

    Fax: +82-31-888-9575

    Email: ccadd.snu@gmail.com